According to experts from the Ministry of Science, Technology and Environment (Citma), the facility has also been able to triple the satisfaction of domestic demand and contributes to lowering hospital expenses.
They explained that the process began with a project undertaken by entity professionals aiming to develop the pharmaceutical formula for the medicine, determine the technology needed for its application and carry out laboratory tests.
The analytical-chemical and microbiological methods were also validated, while durability and quality standards were studied and verified before the drug was introduced to hospital institutions in 2013.
The Citma experts also noted that the medicine is the only one of its kind used in the country, with the island able to manufacture three times the amount it previously imported.
The development process included revision of bibliographical material, cost and formula studies, price assessments, identifying raw materials, developing analysis methods, laboratory work and industrial and pilot studies.
Before being launched onto the market the product was approved by the entity's Technical Council and Advanced Organization of Enterprise Management (OSDE) BioCubaFarma.
It also received validation from the National Institutes of Oncology, Radiology, Neurology and Neurosurgery, as well as the Frank Pais Orthopedic Hospital and General Calixto Garcia University Hospital, in addition to the Center for State Control of Medicine Quality health registry.
The developers of Meropenem500 and 1,000mg were awarded the Citma 2015 technological innovation prize.
The 8 de Marzo Pharmaceutical Enterprise is affiliated with the BioCubaFarma Group and was inaugurated in 1981 in the Havana municipality of Cotorro by Vilma Espin in honor of International Women's Day. / By Lino Luben Perez - ACN.